MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05522namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20260211114142.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
260207s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.32 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.32 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.09.M.Sc.2025.Fa.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Fatma Salah-Elden Mohamed Eltyar, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Potential anti-inflammatory effect of ticagrelor on adjuvant‐induced arthritis in rats / |
| Statement of responsibility, etc. |
by Fatma Salah-Elden Mohamed Eltyar ; Supervision Dr. Hala Fahmy Zaki, Dr. Rehab Mahmoud Mohamed El-Sayed, Dr. Dalia Mostafa El-Tanbouly. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تأثير التيكاجريلور الممكن المضاد للإلتهابات في التهاب المفاصل المحدث بالمواد المشاركة في الجرذان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
124 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 89-120. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Ferroptosis is critical in progressing and exacerbating rheumatoid arthritis (RA) and other inflammatory joint diseases. Inhibition of the P2Y12 receptor, which is chemoreceptor for adenosine diphosphate (ADP), reduced iron overload in macrophages displaying an anti-inflammatory response. Herein, the ameliorative effect of ticagrelor, a reversible P2Y12 inhibitor, against adjuvant-induced arthritis (AIA) in rats was investigated, with a special emphasis on the possible modulation of some inflammatory signals linked to ferroptosis. Particularly, correlation analyses were conducted between nod-like receptor protein 3 (NLRP3) and all assessed parameters. Four groups of rats were assigned: control group, AIA group (0.1 ml intradermal injection of complete Freund's adjuvant), Ticagrelor group (30 mg/kg, p.o.), and Ticagrelor + AIA group. Ticagrelor exhibited an anti-arthritic effect, evidenced by significant improvements in both macroscopic and histopathological alterations. It effectively inhibited ferroptosis, indicated by a marked upregulation of the ferroptotic inhibitors, solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4) and ferritin heavy chain 1 (FTH1), along with a notable reduction in the ferroptotic promoters, P53, acyl-CoA synthetase long-chain family member 4 (ACSL4) and arachidonic acid 15-lipoxygenase-1 (ALOX15). It reduced tumor necrotic factor-alpha (TNF-α) and various chemokines (RANTES, MIP-1α, eotaxin-3) to suppress matrix metalloproteinases expression. Furthermore, ticagrelor decreased NLRP3 expression to pinpoint its anti-inflammatory effect. Overall, amending the P53/SLC7A11/ALOX15 axis by ticagrelor mediated its anti-inflammatory and anti-ferroptotic effects. These findings provide preliminary experimental evidences for further investigating the potential impacts of ticagrelor as a treatment for RA |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
التهاب المفاصل الروماتويدي هو مرض مناعي ذاتي يتميز بنمو غير طبيعي للغشاء الزليلي، مما يسبب التهابًا. يهاجم هذا النمو المفرط الغضروف والعظام، مما يؤدي إلى تدهور تدريجي في المفاصل.<br/>افترضت هذه الدراسة أن تدرس الدور المحتمل لمسار P53/(SLC7A11)/ (ALOX15) في التأثير المفترض المضاد للحديد لدواء تيكاجريلور، ولتوضيح دوره المحتمل في تعديل التهاب الغشاء الزليلي من خلال دراسة دور الكيموكينات المختلفة، وهي RANTES/CCL5,(MIP-1α)/CCL3، eotaxin3/CCL26 بالإضافة إلى (NLRP3) في نموذج الجزذان لالتهاب المفاصل المُستحدثّ بالمواد المساعدة ، كآليات جديدة تكمن وراء الإمكانات العلاجية لدواء تيكاجريلور في مكافحة التهاب المفاصل الروماتويدي.<br/>تم إحداث التهاب المفاصل الروماتويدي باستخدام مادة فريوند المساعدة (0.1) مل جرعة واحدة، تحت الجلد) في مخلب الجرذ الأيسر، وتمت إذابة التيكاجريلور في 4 % ثنائي ميثيل سلفوكسيد (DMSO)، وأُعطي للجرذان (30 ملغ/كغ، عن طريق الفم) طوال فترة الدراسة (21 يومًا). تم توزيع 32 جرذًا ذكرًا من جرذان ويستار البيضاء عشوائيًا على 4 مجموعات (عددها 8 لكل مجموعة) |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology and Toxicology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
أدوية وسموم |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Rheumatoid arthritis |
| -- |
Ticagrelor |
| -- |
Ferroptosis |
| -- |
SLC7A11 |
| -- |
ALOX15 |
| -- |
NLRP3 |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hala Fahmy Zaki |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rehab Mahmoud Mohamed El-Sayed, |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dalia Mostafa El-Tanbouly |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Hala Fahmy Zaki |
| -- |
Rehab Mahmoud Mohamed El-Sayed |
| -- |
Dalia Mostafa El-Tanbouly |
| Universities |
Cairo University |
| Faculties |
Faculty of Pharmacy |
| Department |
Department of Pharmacology and Toxicology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |